The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.
Why do you have to go round all boards to prove how " good " you are ? Who are you to think that you know more then the scientist who are working on these bios ? What makes you think that you have the knowledge needed to rubbish other shares ? I trust all those scientist and bio companies who dectate their lives, money and energy on their work. I am sure they know what they are doing.
I would ignore all the recommended post inanaco gets. His " group " just followes him around and will recommed anything he writes
Correct me if I am mistaken, but I think that you were told my ADIM to stop posting any recommendation of shares on bb which have nothing to do with your recommendation. Recommend your share on its bb.
I have to agree with you. No one of us is a scientist and pretending to be one does not help anyone. Remember what they say " a little knowledge is a dangerous thing. " All those who are buying huge chunks of this share cannot all be wrong. Everyone has to do his/her research then if one does buy it is buy and hold.
Gemfields ups output while lowering cost of production The timing of auctions saw half-year revenues dip at coloured gem stones producer Gemfields (LON:GEM), but the company should pick up the slack in the second half. The group has three auctions lined up for the second half of its financial year, which should balance out full year revenues, with the group confident that sales throughout the first half of 2013 will be well supported by the expansion of marketing activities across a broader target market. Revenue in the six months to the end of December 2012 slipped to US$27.7mln from US$45.7mln in the corresponding period of 2011. The group held only one rough auction during the reporting period, as against two in the same period of 2011 Profit before tax was US$9.43mln, against US$30.8mln the year before, while underlying earnings (EBITDA) came in at US$19.5mln, versus US$32.2mln a year earlier. Cash in hand at the end of the year totalled US$27.9mln, down from US$32.4mln at the end of 2011. On the operational side, the group achieved a substantial improvement in the average production cost, lowering it to US$0.57 per carat of emerald and beryl from US$0.83 per carat. In the six month period Gemfields produced 14.5mln carats of emerald and beryl, up from 8.8mln carats the year before. Since the end of the period the group has completed its acquisition of 100% of the iconic Fabergé jewellery brand and named celebrated actress Mila Kunis as its global brand ambassador. “We have expanded our footprint substantively with the commencement of the ruby bulk sampling operation in Mozambique, ensured that all of our core projects are well capitalised as and where required, continued to retain healthy cash and stock balances and have finalised the acquisition of Fabergé. We have also, at the same time made good progress on our marketing campaigns and through our collaboration with Mila Kunis, continued to position Gemfields' ethical coloured gemstones as the gemstone of choice," said chief executive officer Ian Harebottle.
Good morning, what do you make of that £37.22 k trade at 17:48 . It is being shown as a buy, if it is a buy something very funny is going on here
Who is buying these very large amounts ?
Good morning merv... You are right something is going on with this share. 700k @ 5.20 for the value of £36.40k on a down day like today must mean something !
Good morning agema. to me he seems more than a " bit cheesed off ". Gemfields is a good share to me in at these prices and at this time. Some wanted it to remain just a mining company and sold after the merger with Faberge. In my opinion this will prove to be a very good deal for GEM and many will regret selling
Gemfields names Mila Kunis as brand ambassador 11:09 am by John Harrington Coloured gems producer Gemfields (LON:GEM) has announced glamorous actress Mila Kunis as the face of its new print advertising campaign “While in Africa, I learned that the entire journey that each Gemfields stone takes is carefully considered and that the environment and the local communities where its mines are located are held in the highest regard,” said Kunis The company said Kunis was chosen for her natural beauty, versatility, intelligence and love of rare coloured gems. The actress will be featured in a global advertising programme that will run in publications such as Vogue, Vanity Fair, Bazaar and W. The advertising blitz is just one of many initiatives in a multi-pronged consumer campaign that Gemfields will roll out for 2013. A newly revamped website will launch this spring, enabling consumers to learn about the brand’s initiatives and commitment to sustainability while receiving an in-depth education on coloured gemstones. In March, the brand will debut a collection of exclusive coloured gemstone jewellery designed in collaboration with 37 international designers. Kunis recently toured Gemfields’ Zambian mine, Kagem, to check out the company’s environmentally friendly mining practices. “I truly believe in Gemfields’ mission of ethical mining, and I absolutely have fallen in love with the rarity, beauty and history of emeralds,” she said.
MARKET REPORT: Silence shares will be golden By Geoff Foster PUBLISHED:20:50 GMT, 10 September 2012| UPDATED: 20:50 GMT, 10 September 2012 There has been a kind of hush about Silence Therapeutics for too long. It’s because many long suffering private investors have given up the ghost, having watched the gene therapy group over the past few years promise much, but deliver very little. But industry gossip now suggests that things are looking up. Now under new management, led by chairman Jerry Randall, and a war chest in place to support growth, word is the shares could soon set pulses racing. They firmed 0.17p, or 4.4 per cent, to 2.23p yesterday after the company announced the successful pre-clinical trials for its Atu111 drug used for treating acute lung injury. Shop broker Singer Capital Markets says it is now well positioned to attempt to crystallise inherent value in its potentially ‘game changing’ RNA-based technology. Silence specialises in technology that shuts down target genes by a process known as RNAi interference, which could in turn stop diseases from forming. With a market value of only £33m, it has a portfolio of treatments which apparently puts its US peers in the shade. Regulus Therapeutics, soon to float on Nasdaq with a valuation of around £150m makes Silence look dirt cheap. Shrewd investors have been piling into the stock of late now that the company is in the best of health A notable fan is Richard Griffiths, the entrepreneur and former boss and founder of Evolution Securities. He continues to fill his boots and now sits on 7.1 per cent or 103.9m shares Read more: http://www.thisismoney.co.uk/money/markets/article-2201185/MARKET-REPORT-Silence-shares-golden.html#ixzz2KZjjxsdh Follow us: @MailOnline on Twitter | DailyMail on Facebook
Please do not feel offended because I said that you seem to be new to investing. I just looked at your profile and you are anything but that. Not only that but if you are invested in all the shares you write about, you can teach others a thing or two ! GL with your investments.
Its late.... good night
I know that you are not very good at English ( you say so yourself ) but I thought that you can write without contradicting yourself ! How can you write that I said " oh its too long " ( and it was long 50 pages and yes I told you that did not read it ) and then go on to write ... " nobody spotted it ..... and you didn't either .... so how smart are you " . So.... I could not spot whatever you spotted ( if there really was something to spot ) for the very simple reason that I did not read it . You know that we can go on and on, so lets call it a day. You cannot win with me , never GL